Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(2):176-177; doi:10.1093/jnci/djk023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ioannidis, J. P. A.
Right arrow Articles by Pavlidis, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ioannidis, J. P. A.
Right arrow Articles by Pavlidis, N.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Response: Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis

John P. A. Ioannidis, Davide Mauri, Nikolaos P. Polyzos, Nicholas Pavlidis

Affiliations of authors: Department of Hygiene and Epidemiology (JPAI, NPP) and Department of Medical Oncology (DM, NP), University of Ioannina School of Medicine, Ioannina, Greece

Correspondence to: John P. A. Ioannidis, MD, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, University Campus, Ioannina 45110, Greece (e-mail: jioannid@cc.uoi.gr).

The first 10% of the full text of this article appears below.

Bria et al. assert that phase II trials should not be included in analyses of survival simply because these trials do not have survival as the primary objective but only as a secondary objective. However, this point goes against the fundamental concept and practice that a meta-analysis should be systematically inclusive. An inclusive . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis
Emilio Bria, Paolo Carlini, Francesco Cognetti, Edmondo Terzoli, and Diana Giannarelli
J Natl Cancer Inst 2007 99: 176. [Extract] [Full Text] [PDF]